ArticleJournal of the National Cancer Institute2016
Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer.
Article in Journal of the National Cancer Institute, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Does adding thoracic radiation therapy to systemic chemotherapy increase 1-year and 2-year overall survival in patients with extensive-stage small-cell lung cancer? meta-analysis.Journal of the Egyptian National Cancer Institute · 2025Pooled it
- Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- RNA therapeutic targeting of recalcitrant and rare cancers.Exploration of targeted anti-tumor therapy · 2026Review
- Article
- Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.Thoracic cancer · 2023Article
- Comprehensive analyses of NCancer science · 2022Article
- Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer.Signal transduction and targeted therapy · 2022Article
- An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer.Cancer cell international · 2021Article
- mBMC medicine · 2021Article
- Immunotherapeutic approaches for small-cell lung cancer.Nature reviews. Clinical oncology · 2020Review
- Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019Article
- A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer.Scientific reports · 2019Article
- A step towards valid detection and quantification of lung cancer volume in experimental mice with contrast agent-based X-ray microtomography.Scientific reports · 2019Article
- Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- What's New in SCLC? A Review.Neoplasia (New York, N.Y.) · 2017Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27247352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.